A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries

Artigo Revisado por pares

1992; Adis, Springer Healthcare; Volume: 1; Issue: 5 Linguagem: Inglês

10.2165/00019053-199201050-00006

ISSN

1179-2027

Autores

Brenda Leese, John Hutton, Alan Maynard,

Tópico(s)

Health Systems, Economic Evaluations, Quality of Life

Ver no editor

Altmetric

PlumX